No Data
No Data
Editas Cut to Equal Weight by Wells Fargo Over Reni-cel Positioning
Why Beam Therapeutics (BEAM) Is the Worst ARK Stock to Buy According to Short Sellers
A Quick Look at Today's Ratings for Beam Therapeutics(BEAM.US), With a Forecast Between $42 to $80
Beam Therapeutics Price Target Maintained With a $80.00/Share by HC Wainwright & Co.
Beam Therapeutics Analyst Ratings
Promising Early Data and Innovative Approaches Lead to Buy Rating for Beam Therapeutics